About Urcosimod (Formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye ...

OKYO plans a 40- patient OK-101 open-label clinical trial with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with NCP Second clinical ...

--OKYO Pharma Limited, a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved ...

Gary S. Jacob, Ph.D., Chief Executive Officer of Okyo Pharma, commented: "We are thrilled to announce that OK-101 has been granted the name urcosimod, marking an important step in its development as a ...